Literature DB >> 10618571

Continuous intravenous quinidine infusion for the treatment of atrial fibrillation or flutter: a case series.

N M Allen LaPointe1, P Li.   

Abstract

BACKGROUND: The purpose of the study was to evaluate a continuous intravenous quinidine infusion (CIQI) for the treatment of cardiac arrhythmias in critically ill patients. METHODS AND
RESULTS: A 2-year retrospective review was conducted in adult patients receiving a CIQI for cardiac arrhythmias. Patient demographics, baseline laboratory values, indication for quinidine, dose, duration of therapy, efficacy, adverse events, and serum concentration were among the collected data. All patients were critically ill and receiving quinidine for the treatment of atrial arrhythmias. Quinidine was effective in 14 (61%) of the 23 enrolled patients. Ninety-one percent of the patients received the CIQI after surgery. A total of 8 (35%) patients died. Four (17%) patients had hypotension possibly attributed to the quinidine.
CONCLUSIONS: A continuous intravenous infusion of quinidine gluconate may be effective in patients in whom other agents are contraindicated or have failed. However, as with all antiarrhythmic agents, risks of therapy must be carefully considered.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618571     DOI: 10.1016/s0002-8703(00)90317-x

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  2 in total

1.  High risk of QT interval prolongation and torsades de pointes associated with intravenous quinidine used for treatment of resistant malaria or babesiosis.

Authors:  Heather A Wroblewski; Richard J Kovacs; Joanna R Kingery; Brian R Overholser; James E Tisdale
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

2.  Quinidine for pharmacological cardioversion of atrial fibrillation: a retrospective analysis in 501 consecutive patients.

Authors:  Bernhard Schwaab; Alexander Katalinic; Uta Maria Böge; Jürgen Loh; Peter Blank; Tatjana Kölzow; Dirk Poppe; Hendrik Bonnemeier
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-04       Impact factor: 1.468

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.